NCT04008238View on ClinicalTrials.gov

Prospective Identification of Predictive Biomarkers of Trabectedin Efficacy in Non-L Soft-tissue Sarcoma Patients

NAActive, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 6, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Soft Tissue Sarcoma AdultUndifferentiated Pleomorphic SarcomaEpithelioid SarcomaSolitary Fibrous TumorsHemangioendotheliomaDesmoplastic Round Cell TumorSynovial Sarcoma
Interventions
DRUG

Trabectedin

\- Trabectedin will be prescribed as per market authorization and will be administered by intraveinous infusion (1,5 mg/m²) every 3 weeks. A treatment cycle is defined as a 3-weeks period

Trial Locations (1)

33076

Institut Bergonie, Bordeaux

Sponsors

Lead Sponsor

Institut Bergonié
All Listed Sponsors
lead

Institut Bergonié

OTHER